Loading...
Budget Impact Of Including Avelumab As A Second-Line Treatment For Locally Advanced Or Metastatic Urothelial Cancer In The United States: Commercial And Medicare Payer Perspectives
OBJECTIVE: To estimate the budget impact of introducing avelumab as a second-line (2L) treatment option for patients with locally advanced or metastatic urothelial cancer (mUC) from the perspective of a US third-party payer (commercial and Medicare). METHODS: A budget impact model (BIM) with a three...
Na minha lista:
| Udgivet i: | Clinicoecon Outcomes Res |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Dove
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6850681/ https://ncbi.nlm.nih.gov/pubmed/31807039 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEOR.S215069 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|